Traders purchased shares of Celgene Corp. (NASDAQ:CELG) on weakness during trading on Friday. $156.79 million flowed into the stock on the tick-up and $115.61 million flowed out of the stock on the tick-down, for a money net flow of $41.18 million into the stock. Of all equities tracked, Celgene Corp. had the 5th highest net in-flow for the day. Celgene Corp. traded down ($0.74) for the day and closed at $115.53

A number of research firms have recently issued reports on CELG. Zacks Investment Research upgraded shares of Celgene Corp. from a “hold” rating to a “buy” rating and set a $130.00 target price for the company in a research note on Friday. BTIG Research upgraded shares of Celgene Corp. from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $116.14 to $138.00 in a research report on Wednesday. Vetr upgraded shares of Celgene Corp. from a “sell” rating to a “hold” rating and set a $111.26 price objective for the company in a research report on Monday, August 1st. Stifel Nicolaus restated a “buy” rating and issued a $138.00 price objective on shares of Celgene Corp. in a research report on Tuesday. Finally, Morgan Stanley restated a “hold” rating and issued a $120.00 price objective on shares of Celgene Corp. in a research report on Wednesday. Four analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the company. Celgene Corp. currently has an average rating of “Buy” and a consensus target price of $137.65.

The stock has a market cap of $89.55 billion and a P/E ratio of 48.83. The stock’s 50 day moving average price is $104.45 and its 200 day moving average price is $103.46.

Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.05. During the same quarter in the previous year, the business posted $1.23 earnings per share. The company earned $2.74 billion during the quarter, compared to analyst estimates of $2.70 billion. The company’s revenue for the quarter was up 20.9% compared to the same quarter last year. Equities analysts predict that Celgene Corp. will post $5.77 earnings per share for the current year.

In other Celgene Corp. news, insider Robert J. Hugin sold 75,000 shares of the firm’s stock in a transaction on Monday, June 20th. The shares were sold at an average price of $100.16, for a total value of $7,512,000.00. Following the completion of the sale, the insider now directly owns 1,122,201 shares in the company, valued at $112,399,652.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Robert J. Hugin sold 100,000 shares of the firm’s stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $110.00, for a total transaction of $11,000,000.00. Following the completion of the sale, the insider now owns 1,022,201 shares of the company’s stock, valued at $112,442,110. The disclosure for this sale can be found here.

A number of large investors recently bought and sold shares of CELG. Twin Capital Management Inc. boosted its stake in Celgene Corp. by 0.7% in the fourth quarter. Twin Capital Management Inc. now owns 23,890 shares of the biopharmaceutical company’s stock worth $2,861,000 after buying an additional 160 shares during the last quarter. Sawtooth Asset Management Inc. boosted its stake in Celgene Corp. by 16,596.4% in the fourth quarter. Sawtooth Asset Management Inc. now owns 18,533 shares of the biopharmaceutical company’s stock worth $2,220,000 after buying an additional 18,422 shares during the last quarter. Morgan Stanley boosted its stake in Celgene Corp. by 7.9% in the fourth quarter. Morgan Stanley now owns 3,883,304 shares of the biopharmaceutical company’s stock worth $465,065,000 after buying an additional 284,929 shares during the last quarter. Mutual of America Capital Management LLC boosted its stake in Celgene Corp. by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 109,006 shares of the biopharmaceutical company’s stock worth $13,055,000 after buying an additional 549 shares during the last quarter. Finally, Gulf International Bank UK Ltd boosted its stake in Celgene Corp. by 2.2% in the fourth quarter. Gulf International Bank UK Ltd now owns 235,307 shares of the biopharmaceutical company’s stock worth $28,180,000 after buying an additional 5,100 shares during the last quarter.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.